Literature DB >> 20662720

Seroprevalence of antibody to mumps virus in the US population, 1999-2004.

Preeta K Kutty1, Deanna M Kruszon-Moran, Gustavo H Dayan, James P Alexander, Nobia J Williams, Philip E Garcia, Carole J Hickman, Geraldine M McQuillan, William J Bellini.   

Abstract

BACKGROUND: In 2006, the largest mumps outbreak in the United States in 20 years occurred. To understand prior mumps seroprevalence and factors associated with the presence of antibody to mumps virus, data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were analyzed.
METHODS: A mumps virus-specific enzyme immunoassay was used to measure the seroprevalence of serum immunoglobulin G (IgG) antibody among NHANES participants aged 6-49 years. Participants were grouped on the basis of 10-year birth cohorts, 95% confidence intervals (CIs) were calculated using SUDAAN software, and logistic regression was used to identify independent predictors.
RESULTS: The overall age-adjusted seroprevalence of IgG antibody to mumps virus during 1999-2004 was 90.0% (95% CI, 88.8%-91.1%). Seroprevalence was higher among US-born non-Hispanic blacks (96.4% [95% CI, 95.5%-97.2%]) and non-US-born Mexican Americans (93.7% [95% CI, 92.0%-95.2%]). Seroprevalence was significantly lower in the 1967-1976 birth cohort (85.7% [95% CI, 83.5%-87.8%]). The variables sex, education, and race/ethnicity/birthplace were independent predictors in at least 1 of the birth cohorts.
CONCLUSIONS: The overall estimate of 90.0% is at the lower end of the estimated population immunity (90%-92%) needed to achieve herd immunity. Lower seroprevalence among groups suggest that they represent populations at an increased risk. For mumps control, high vaccine coverage and high population immunity must be achieved and maintained.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662720     DOI: 10.1086/655394

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

2.  Identification of immune correlates of protection in Shigella infection by application of machine learning.

Authors:  Jorge M Arevalillo; Marcelo B Sztein; Karen L Kotloff; Myron M Levine; Jakub K Simon
Journal:  J Biomed Inform       Date:  2017-08-09       Impact factor: 6.317

3.  Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.

Authors:  Benjamin M Stermole; Greg A Grandits; Mollie P Roediger; Brychan M Clark; Anuradha Ganesan; Amy C Weintrob; Nancy F Crum-Cianflone; Tomas M Ferguson; Grace E Macalino; Michael L Landrum
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

4.  Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India.

Authors:  Jeevan Malaiyan; Thatchayini Duraipandian; Aparna Warrier; Thangam Menon
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

5.  Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.

Authors:  Mohammed Ata Ur Rasheed; Carole J Hickman; Marcia McGrew; Sun Bae Sowers; Sara Mercader; Amy Hopkins; Vickie Grimes; Tianwei Yu; Jens Wrammert; Mark J Mulligan; William J Bellini; Paul A Rota; Walter A Orenstein; Rafi Ahmed; Srilatha Edupuganti
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-03       Impact factor: 12.779

6.  Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.

Authors:  L W Ang; F Y Lai; S H Tey; J Cutter; L James; K T Goh
Journal:  Epidemiol Infect       Date:  2012-09-24       Impact factor: 4.434

7.  Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010.

Authors:  Emmaculate J Lebo; Deanna M Kruszon-Moran; Mona Marin; William J Bellini; Scott Schmid; Stephanie R Bialek; Gregory S Wallace; Huong Q McLean
Journal:  Open Forum Infect Dis       Date:  2015-02-20       Impact factor: 3.835

8.  Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Authors:  Christina Poethko-Müller; Annette Mankertz
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

9.  Blood Lead Concentrations and Antibody Levels to Measles, Mumps, and Rubella among U.S. Children.

Authors:  Todd A Jusko; Kyra Singh; Elizabeth A Greener; Marina Oktapodas Feiler; Kelly Thevenet-Morrison; B Paige Lawrence; Robert O Wright; Sally W Thurston
Journal:  Int J Environ Res Public Health       Date:  2019-08-22       Impact factor: 3.390

10.  Black African and Latino/a identity correlates with increased plasmablasts in MS.

Authors:  Kiel M Telesford; Ulrike W Kaunzner; Jai Perumal; Susan A Gauthier; Xian Wu; Ivan Diaz; Mason Kruse-Hoyer; Casey Engel; Melanie Marcille; Timothy Vartanian
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.